Tag: Health Care

Displaying 141 - 160 of 795 results.

(Health Care as the New Cement; and Actions Against the Pharmaceutical Industry as a Game of Whack-a-Mole)
This is an interview with Commissioner Leary conducted by the ABA Antitrust Section Health Care Committee Newsletter, published in the ABA's Antitrust Health Care Chronicle, October 2005, Vol. 19, No. 3.
This article is based on a speech delivered at the Saint Louis University Health Law Symposium on April 12, 2002, and is published in issue 47:2 of the Saint Louis University Law Journal, at page 217.
This article is a written version of a speech given at a forum on Antitrust and Health Care jointly sponsored by the Health Lawyers Association and the ABA Sections of Antitrust Law and Health Law (May 15, 2003), and is published in Antitrust, Spring 2004, Volume 18, No. 2, at 23.
The Federal Trade Commission plans to hold a one-day public workshop to examine developments in the health care sector relating to “clinical integration” among health care providers. Clinical integration is a term used to describe certain types of collaborations among otherwise...
This quasi-academic conference, organized by Stanford health economist Dan Kessler, brought together academics and health policy makers to examine the production of and use of health care market information by consumers and employers. It examined some effects of competition in...
The FTC held a workshop to explore alternate approaches to reducing deceptive claims in advertising for weight-loss products. Following up on the issuance of the FTC staff report, Weight-Loss Advertising: An Analysis of Current Trends, the workshop gave the FTC staff and interested...
The FTC held a public workshop on the implications of competition law and policy for health care financing and delivery. The workshop considered the impact of competition law and policy on the cost, quality, and availability of health care, and the incentives for innovation in the...
I. INTRODUCTION It is an honor to be here and join such an impressive group of practitioners, government officials, judges, academics and economists to discuss the cutting edge issues confronting health care and antitrust.
As the title indicates, the settlement of pharmaceutical patent disputes is a subject that I have already addressed.(1) You may wonder why I am visiting it again. When I first discussed the issue last November, The Federal Trade Commission ("the Commission") had brought only two cases,(2) with a...
Good afternoon. It is a pleasure to be here today to discuss the antitrust analysis of physician networks and other integrated delivery systems. As always, I must remind you that my remarks today reflect only my own views and are not necessarily those of the Commission or of any other Commissioner.
Good morning. It is a pleasure to be here today to introduce this morning's program on the antitrust analysis of hospital mergers, HMO mergers and physician networks. I would like to express my sincere thanks to General Burson for his kind introductory remarks and for hosting this conference. As...
Good afternoon. Thank you for the opportunity to address the 30th Annual Antitrust Institute on Healthcare Antitrust Developments on what is a very interesting and exciting topic. Let me say before I begin that the views I express are entirely my own and do not necessarily represent the views of...
Mr. Chairman, the Federal Trade Commission thanks you and the members of the Committee for inviting us again this year to present the Commission's views on a proposed antitrust exemption to allow physicians and other health care professionals to engage in collective bargaining with health plans.

Pages